medwireNews

The JAVELIN Lung 101 study suggests that the PD-L1 inhibitor avelumab plus the third-generation ALK inhibitor lorlatinib may be a feasible combination in non-small-cell lung cancer patients with heavily pretreated, advanced ALK-positive disease.

Two opposing sets of phase III results regarding the effect of denosumab on the recurrence of hormone receptor-positive nonmetastatic breast cancer have been presented at the ASCO Annual Meeting 2018 in Chicago, Illinois, USA.

A significant overall survival benefit with the use of maintenance chemotherapy has been demonstrated by the RMS2005 trial of children who have completed standard treatment for high-risk, nonmetastatic rhabdomyosarcoma.

Research findings can reassure patients with mild asthma that the long-term prognosis is good, with only a tenth of patients transitioning to more severe disease over 10 years.

The addition of abatacept to standard therapy does not increase the rate of complete renal response among patients with lupus nephritis, phase III study findings show.

Patients with juvenile idiopathic arthritis who are treated with etanercept do not have a higher risk for developing uveitis than those given methotrexate, results of a UK cohort study suggest.